Back to Resources

Ultomiris Maintains Its Promotional Standing in the European IgAN Market during the Second Quarter of 2026

Market Highlights

  • AstraZeneca/Alexion highlighted positive clinical results supporting Ultomiris in IgAN and announced FDA Priority Review for the brand.

  • Novartis’ Vanrafia featured positive clinical outcomes in kidney function.

Questions about this SnapShot or other markets?

U.S. MARKETS

Christine Alongi
alongi@dtwresearch.com

GLOBAL MARKETS

Robin Cefalo
cefalo@dtwresearch.com

SOCIAL MEDIA MARKETS

Andrew Carney
carney@dtwresearch.com

Get in Touch

Want to see what we can do for your organization? We’ll walk you through CDP, train your team, and stay close with ongoing support.

Contact us